Coagulation Factor Viia Recombinant Human: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Coagulation Factor Viia Recombinant Human. Educational only — not medical advice.
Labeled uses
SEVENFACT is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors. Limitation s of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency.
Source: FDA labeling via NIH DailyMed (set b23ad666…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.